Two Potential Drug Pipeline "Disruptors" to Watch

Two Potential Drug Pipeline "Disruptors" to Watch

Kalorama's new report isolates potential drug pipeline "disruptors," new pharmaceuticals that could change future market leadership because of their effectiveness in a given disease area. In this article we look at two of them, a drug pipeline candidate in asthma and a drug pipeline candidate in lymphoma.


Lowering Drug Prices Isn't Easy

Lowering Drug Prices Isn't Easy

Drug prices are a popular target of politicians and advocacy groups and patients themselves. Bad actors such as Mylan have given the industry a poor image. Now President Trump joined the chorus of voices saying prices are too high. But what's involved in pricing? Could steps to reduce pricing lead to worse care?


At a Crossroads, Pharma Clients Seek Flexibility, Efficiency in CRO Market

At a Crossroads, Pharma Clients Seek Flexibility, Efficiency in CRO Market

Kalorama Information also offers the report Proteomics Research Markets: Instruments (Mass Spectrometry, Liquid Chromatography, Electrophoresis), Disease Areas (Oncology, Cardio/Blood, Neurology, Other) Market Share and Trends for market insights into selected products used in biomarker and drug discovery research.

Tracked through seven editions of Kalorama Information’s Outsourcing in Drug Discovery , pharmaceutical research and development (R&D) is now pinned between building market pressure...


After Allergan Merger Halt, Vaccines a Focus for Pfizer

New U.S. Treasury regulation has dissuaded Pfizer from its planned merger with Ireland-based Allergan. The two companies agreed on Tuesday to terminate the deal. The tax inversion move would have benefited Pfizer’s profitability and reintroduced the company to the dermatologics market. Pfizer will now consider business divestitures in order to boost its profits. Pfizer previously spun-off its animal health business in 2013, which now operates as the veterinary pharmaceuticals and diagnostics com...